NEW YORK, Sept. 07, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

SAN DIEGO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired DexCom Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024. DexCom is an international company that develops, manufactures, and distributes continuous glucose monitoring systems for diabetes management. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) ...

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of DexCom, Inc. (NASDAQ: DXCM) between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), of the important October 21, 2024 lead plaintiff deadline in the securities class action. SO WHAT: If you purchased DexCom securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a conti ...

LOS ANGELES, Sept. 5, 2024 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against DexCom, Inc. ("DexCom" or "the Company") (NASDAQ: DXCM) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plainti ...

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

NEW YORK, Sept. 5, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of DexCom, Inc. (NASDAQ: DXCM).Shareholders who purchased shares of DXCM during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE: https://securitiesclasslaw.com/securities/dexcom-inc-loss-submission-form/?id=100122&from=4 CLASS PERIOD: January 8, 2024 to July 25, ...

DexCom, Inc. (NASDAQ:DXCM) Conference Call Summary Company Overview - **Company**: DexCom, Inc. - **Industry**: Continuous Glucose Monitoring (CGM) - **Event**: Wells Fargo 2024 Healthcare Conference - **Date**: September 4, 2024 Key Points Industry Growth and Market Potential - The worldwide CGM market grew approximately **22%** in constant currency during the first half of the year, indicating strong demand and growth potential [3] - DexCom believes the CGM market will continue to grow at around **20%** going forward, with significant opportunities in Type 2 diabetes segments [3][4] Competitive Landscape - DexCom is facing competition from Abbott, particularly in the DME (Durable Medical Equipment) channel, where Abbott reportedly holds a **70%** share among Type 2 basal patients [27] - The company acknowledges the need to improve its sales force effectiveness and DME relationships to regain market share [4][28] Sales Force and DME Challenges - DexCom expanded its sales force in 2023 to improve reach and capture more prescriptions, but this led to confusion and a temporary decline in referrals to DME providers [21][23] - The company is retraining its sales representatives to emphasize channel neutrality and improve relationships with DME partners [23][25] Product Development and Launches - DexCom is confident about launching a **15-day** product for the G7 line in **2025**, pending FDA approval [9][11] - The Stelo product, recently launched, is expected to contribute significantly to growth, with a target of **$40 million** in revenue in the first year [64][72] Financial Guidance and Growth Projections - DexCom has guided for **14%** growth in 2025, with expectations of stabilizing DME market share and improved sales force productivity [15][70] - The company anticipates a **1% to 3%** growth in Q3, with a rebound to **5% to 10%** growth in Q4 as sales force effectiveness improves [43][46] International Market Insights - The international CGM market is expected to grow in the mid-to-upper teens, with challenges in Japan due to distributor transitions [41][42] - DexCom is optimistic about future growth as reimbursement categories open up in various geographies [42] Customer Feedback and Market Demand - Initial feedback for the Stelo product has been positive, with strong app downloads and customer satisfaction reported [48][49] - The pricing strategy for Stelo, set at **$89 to $99** per month, is based on extensive market research, and the company is confident in its premium pricing model [54][55] Conclusion and Future Outlook - DexCom emphasizes that current challenges are execution-related and not indicative of product quality or pipeline issues [75][76] - The management remains optimistic about the company's long-term growth potential, aiming to address current execution hiccups and capitalize on market opportunities [76]

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- The law firm of Robbins Geller Rudman & Dowd LLP announces purchasers or acquirers of DexCom, Inc. (NASDAQ: DXCM) securities between January 8, 2024 and July 25, 2024, both dates inclusive (the “Class Period”), have until October 21, 2024 to seek appointment as lead plaintiff of the DexCom class action lawsuit. Captioned Alonzo v. DexCom, Inc., No. 24-cv-01485 (S.D. Cal.), the DexCom class action lawsuit charges DexCom as well as certain of DexCom’s top executiv ...

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against DexCom, Inc. (NASDAQ: DXCM) and certain of the Company’s senior executives. If you invested in DexCom, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/dexcom-inc. Investors have until October 21, 2024 to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) an ...

SAN FRANCISCO, Sept. 02, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges DexCom, Inc. (NASDAQ: DXCM) investors who suffered substantial losses to submit your losses now. The firm also encourages persons with knowledge who may be able to assist in the investigation to contact its attorneys. Class Period: Jan. 8, 2024 – July 25, 2024Lead Plaintiff Deadline: Oct. 21, 2024Visit: www.hbsslaw.com/investor-fraud/DXCM Contact the Firm Now: DXCM@hbsslaw.com                                            844-916-0895 DexCo ...